CAR-T Update: Kite's Filing Coming Soon
With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
You may also be interested in...
Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.